Immunotherapy in Melanoma | Specialty

TLR9 Agonist May Reverse Resistance to PD-1 Inhibition in Melanoma

April 17th 2018

Combination use of CMP-001, an intratumoral toll-like receptor 9 agonist, and pembrolizumab (Keytruda) showed clinical activity in reversing PD-1 checkpoint inhibition resistance in patients with metastatic melanoma.

Adjuvant Pembrolizumab Improves RFS in Stage III Melanoma

April 15th 2018

Adjuvant pembrolizumab (Keytruda) reduced the risk of recurrence or death by 43% in patients with resected, high-risk stage III melanoma, according to phase III results from the EORTC 1325-MG/KEYNOTE-054 trial.

Dr. Andtbacka Discusses Next Steps With T-VEC in Melanoma

April 14th 2018

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses the future of talimogene laherparapvec (T-VEC; Imlygic) in the treatment of patients with melanoma.

Dr. Weber Discusses Advancements in Melanoma

April 7th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program, NYU Langone’s Perlmutter Cancer Center, 2016 Giant of Cancer Care® in Melanoma, discusses exciting recent advancements for patients with melanoma.

Pembrolizumab Combo Fails in Melanoma

April 6th 2018

The combination of the PD-1 inhibitor pembrolizumab and the IDO1 inhibitor epacadostat failed to improve progression-free survival versus single-agent pembrolizumab in patients with unresectable or metastatic melanoma, according to findings from the phase III ECHO-301/KEYNOTE-252 trial.

Nivolumab/Ipilimumab Doubles Intracranial Response in Melanoma Brain Mets

April 6th 2018

The combination of nivolumab and ipilimumab induced an intracranial response of 46% in melanoma patients with asymptomatic, untreated brain metastases.

Dr. Sullivan Discusses the Current Treatment of Melanoma

April 4th 2018

Ryan J. Sullivan, MD, instructor of Medicine, Harvard Medical School, assistant in medicine, MGH Cancer Center, Massachusetts General Hospital, discusses the current treatment of patients with melanoma.

Dr. Postow Discusses New Targets in Melanoma

March 27th 2018

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses new targets in melanoma.

Dr. Andtbacka Discusses Combination Therapy in Melanoma

March 23rd 2018

Robert Andtbacka, MD, associate professor in the Division of Surgical Oncology, Department of Surgery at the University of Utah School of Medicine, discusses combination therapy in melanoma.

Dr. Kim Discusses the Impact of the PACIFIC Trial in NSCLC

March 20th 2018

Edward S. Kim, MD, chair, Department of Solid Tumor Oncology, Levine Cancer Institute, discusses the impact of the PACIFIC trial in non–small cell lung cancer (NSCLC).

Dr. Weber on Side Effects of Dabrafenib/Trametinib in Melanoma

March 19th 2018

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, 2016 Giant of Cancer Care® in Melanoma, discusses the side effect profile of dabrafenib (Tafinlar) and trametinib (Mekinist) for patients with melanoma.

Dr. Whitman on the Role of Pembrolizumab in Melanoma

March 15th 2018

Eric Whitman, MD, surgeon, Atlantic Health System, discusses the role of pembrolizumab (Keytruda) in the treatment of patients with melanoma.

Dr. Brahmer Discusses Second-Line Pembrolizumab in NSCLC

March 15th 2018

Julie R. Brahmer, MD, associate professor of oncology, co-director of the Upper Aerodigestive Department, Bloomberg Kimmel Institute for Cancer Immunotherapy, Johns Hopkins Medicine, discusses second-line pembrolizumab (Keytruda) in non–small cell lung cancer.

Guidelines Clarify Management of Immune-Related AEs in Lung Cancer

March 14th 2018

Heather Greene, NP, discusses the safety profile for patients with lung cancer receiving immunotherapy, and the importance for reporting immune-related adverse events.

Locally Advanced NSCLC: Audience Q&A

March 13th 2018

Promising Developments in Locally Advanced NSCLC

March 13th 2018

Improving Care in Locally Advanced NSCLC

March 13th 2018

Tips for Managing NSCLC Patients on Durvalumab Therapy

March 13th 2018

NSCLC: Consolidation Immunotherapy in Practice

March 13th 2018

Chemotherapy Choices in the PACIFIC Trial

March 13th 2018